Prostate Cancer Patient Articles & Analysis
26 news found
Almost all early-stage prostate cancers are androgen-dependent.4 Up to 50% of patients with prostate cancer develop elevated prostate-specific antigen (PSA) levels in their blood after primary therapy (surgery and/or radiation therapy).5 This disease state is called biochemical recurrence (BCR). ...
ByBayer AG
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) ...
ByBayer AG
Nubeqa is already approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
“The number of prostate cancer patients in Japan has increased rapidly in recent years, almost doubling in the past decade. ...
ByBayer AG
“An important part of our mission at Bayer is to transform prostate cancer care and improve patient outcomes at various stages of the disease. ...
ByBayer AG
Darolutamide is being investigated in a broad development program with additional three ongoing or planned large clinical studies, to investigate its potential across prostate cancer patients from the early- to the late-stage of this disease. ...
ByBayer AG
Nubeqa™ (darolutamide), which has the potential to become the standard of care for prostate cancer patients from the early- to the late-stage of this disease, has projected peak sales potential of more than three billion euros. Its market share in the US has already expanded to over 30 percent in non-metastatic castration-resistant ...
ByBayer AG
Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...
The compound is also being investigated in further studies across various stages of prostate cancer. “Darolutamide plus ADT and docetaxel has shown significant benefit in overall survival and a favorable safety profile for patients with metastatic hormone-sensitive prostate cancer,” said Matthew ...
ByBayer AG
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. ...
Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate ...
About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.1 At the time of diagnosis, most men ...
ByBayer AG
Investigators from the University of Pittsburgh School of Medicine have published a clinical study that demonstrates excellent outcomes for localized intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 brachytherapy, commercially known as Cesium Blu. ...
Raise in peak sales expectations follows presentation of positive Phase III trial ARASENS with darolutamide (Nubeqa) in metastatic hormone-sensitive prostate cancer at 2022 ASCO GU Cancers Symposium and publication in The New England Journal of Medicine on February 17, 2022 Broad development program underway with three additional ongoing or ...
ByBayer AG
“These results are an important step forward for the treatment of patients with metastatic hormone-sensitive prostate cancer.” “With the ARASENS results in mHSPC adding to the existing Phase III ARAMIS data in non-metastatic castration-resistant prostate cancer (nmCRPC), darolutamide has now ...
ByBayer AG
Filtricine is developing a human version of the TND diet, Tality, as a medical food to manage cancer. Filtricine is sponsoring a clinical study at Stanford University School of Medicine for the use of Tality in the management of prostate cancer. Tality™ is available to prostate cancer ...
About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. ...
ByBayer AG
The clinical trial results demonstrate the ease of use and performance of SENSEI in prostate cancer surgery and signal potential application in other surgical procedures across major cancer types. ...
Being able to detect – and understand – these cells could be key to non-invasive early cancer detection. In previous studies focusing on prostate cancer patients, X-ZELL was able to identify individual, tumour-associated atypical cells in 10mL blood and visualise them for AI-assisted analysis. ...
MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. ...
ByMiraDx